Provided herein are fusion proteins including at least one binding polypeptide and at least
one unstructured polypeptide. The fusion protein may further include at least one linker …

US9771396B2 - Phase transition biopolymers and methods of use - Google Patents
US9771396B2 - Phase transition biopolymers and methods of use - Google Patents Phase …

The present disclosure describes environmentally responsive polypeptides capable of
displaying stimuli-triggered confor mational changes in a reversible or irreversible manner …

SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O [C@@ H] 1 [C@@
H](O)[C@ H](O)[C@@ H](CN) O [C@@ H] 1O [C@ H] 1 [C@ H](O)[C@@ H](O [C@@ H] 2 …

Disclosed herein are compositions and methods for reducing the antigenicity of molecules.
The antigenicity of a molecule may be reduced or eliminated by conjugating at least one …

A61K47/50—Medicinal preparations characterised by the non-active ingredients used, eg
carriers or inert additives; Targeting or modifying agents chemically bound to the active …

Compositions and methods disclosed herein can help provide improved delivery of non-
natural therapeutic nucleotides for the treatment of diseases such as cancer. An example …

SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O [C@@ H] 1 [C@@
H](O)[C@ H](O)[C@@ H](CN) O [C@@ H] 1O [C@ H] 1 [C@ H](O)[C@@ H](O [C@@ H] 2 …

BACKGROUND [0003] Cancer immune checkpoint therapy has achieved remarkable
clinical successes in various cancers. Current immune checkpoint inhibitors, however, block …

Described herein are unstructured polypeptides lacking any discernible repeat motif. Also
described herein are fusion proteins including at least one of the unstructured polypeptides …